#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
#LCSM Chat @lcsmchat
@steele_bob Hey Bob! Thanks for joining. #lcsm
Brendon Stiles @BrendonStilesMD
If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm
Brendon Stiles @BrendonStilesMD
@aepriceny Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
@JROSE_JNJ @BrendonStilesMD Welcome! #lcsm
Brendon Stiles @BrendonStilesMD
@steele_bob Hi Bob! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm
Henning Willers, MD @HenningWillers
I am here to support @BrendonStilesMD and if possible tall about #lungcancer radiotherapy #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Excited for everyone to be here. Don’t know about all of you…but I am exhausted by 2020. #lcsm https://t.co/dGWaTde8By
Brendon Stiles @BrendonStilesMD
You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Elliot Servais, MD, FACS @ElliotServaisMD
Looking forward to the discussion #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm
#LCSM Chat @lcsmchat
@aepriceny Awesome! #lcsm
Brendon Stiles @BrendonStilesMD
To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twitter.
Judy Yee @JudyYeeMD
RT @grebeccahaines: So proud of @RadiologyACR and this special issue https://t.co/e9SHnlNpiM #healthequity #transgendercare #lcsm #BCAM2020
OncLive.com @OncLive
Registration is now open! 10/8 6pm MT IPC Lung Cancer chaired by D. Ross Camidge, MD, PhD @CUCancerCenter. Register for a Q&A opportunity with our expert faculty #lcsm #oncliveIPC @OncLiveSOSS https://t.co/E7nIYeiRSA
Sara Whitlock @sjwhitlock
Sara here from Ohio #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers Always appreciate your insight! #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Christine Garcia, MD, MPH @christinemphmd
Hi @BrendonStilesMD. Looking forward to the discussion #lcsm! #lcsm
Brendon Stiles @BrendonStilesMD
@sjwhitlock Ahhh...be still my heart! Missing you. Thanks for joining. DOD not the same without you! #lcsm
#LCSM Chat @lcsmchat
@HenningWillers @BrendonStilesMD Always happy to “see” you! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm
#LCSM Chat @lcsmchat
@ElliotServaisMD Thanks for joining us! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Brendon Stiles @BrendonStilesMD
@christinemphmd Thanks for joining! #lcsm
Brendon Stiles @BrendonStilesMD
@christinemphmd Thanks for joining! #lcsm
#LCSM Chat @lcsmchat
@sjwhitlock Hi Sara! #lcsm
Brendon Stiles @BrendonStilesMD
@ElliotServaisMD Thanks for joining! #lcsm
Danielle Pardue @Actorielle
Hi, Friends! Danielle in NC here. So happy to be with you all tonight! #lcsm
#LCSM Chat @lcsmchat
@christinemphmd @BrendonStilesMD Welcome! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Brendon Stiles @BrendonStilesMD
I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnews @genentech. These don’t affect opinions expressed tonight. #lcsm
kristen kimball @KimballKristen
Kris Kimball here from Boston, multitasking and trying to keep it together .... #LCSM
Elliot Servais, MD, FACS @ElliotServaisMD
Elliot Servais, thoracic surgeon, advocate and 2nd ever tweetchat. Happy to be here #lcsm
Upstage Lung Cancer @UpstageLungCanc
Hi, everyone! Honored as always to be a part! #lcsm
Faces of Lung Cancer @LungCancerFaces
Deana in Los Angeles here. Tonight I’ll be tweeting from the @lcsmchat account. #lcsm
Brendon Stiles @BrendonStilesMD
By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has been an amazing year! #lcsm
Brendon Stiles @BrendonStilesMD
@LungCancerFaces @lcsmchat The one and only.... #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm
Elliot Servais, MD, FACS @ElliotServaisMD
Disclosures - Consultant and educator for Intuitive Surgical. My opinions and comments tonight are my own #lcsm
Lung Cancer Sux @LungCancerSux
@BrendonStilesMD Hi from CT! Glorianne here. Hubby diagnosed 10 years ago stage 4 nsclc #LCSM
Danielle Pardue @Actorielle
RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has b…
Brendon Stiles @BrendonStilesMD
In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared at #ESMO20 #lcsm
#LCSM Chat @lcsmchat
@Actorielle Hey you! #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I would like to disclose conflicts – I am the Board Chair of @lcrf_org & have worked with @astrazeneca @pfizer @bmsnew
Brendon Stiles @BrendonStilesMD
Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has b…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately changed our clinical practice #LCSM
Brendon Stiles @BrendonStilesMD
@LungCancerSux Hi. Hope all is well! #lcsm
#LCSM Chat @lcsmchat
@KimballKristen Hey Kris! Same here. Baby on my lap. Squirmy. #lcsm
Nina Davis @ Australian Teacher & Manufacturer @ninadavis
Nina from Melbourne Aus here. Sunny day... COVID cases 7 for Victoria. Awesome day 😷 #lcsm
Erika Hlavacek @ErikaHlavacek
Erika from Chicago here! #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has b…
Brendon Stiles @BrendonStilesMD
Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZyKkuA
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately chang…
mimiprovenzano @MimiProvenzano
#lcsm Hi everybody!
Janet Freeman-Daily @JFreemanDaily
Janet here, LC research advocate in Seattle--smoky haze in the upper atmosphere, but air quality is out of the "good" range. #lcsm
Lung Cancer Sux @LungCancerSux
@BrendonStilesMD Everyone is doing well! Thank goodness! #LCSM
Brendon Stiles @BrendonStilesMD
Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj
#LCSM Chat @lcsmchat
@LungCancerSux @BrendonStilesMD Hey Glorianne! #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZy…
Brendon Stiles @BrendonStilesMD
@MimiProvenzano Another one of my favorites! Who said 2020 is bad? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately chang…
Brendon Stiles @BrendonStilesMD
We will get started soon. First, a few reminders… #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZy…
Aparna Hegde, MD @notahedge
Aparna here from Birmingham #LCSM
Peggy Dennis @peggyddennis
#lcsm Peggy joining from Denver. Hi everyone
#LCSM Chat @lcsmchat
@ninadavis Welcome! #lcsm
Brendon Stiles @BrendonStilesMD
Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat
Debby Keller, MD @debby_keller
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Christine Garcia, MD, MPH @christinemphmd
RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZy…
Brendon Stiles @BrendonStilesMD
If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
#LCSM Chat @lcsmchat
@ErikaHlavacek Hi Erika! #lcsm
Brendon Stiles @BrendonStilesMD
I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
Brandon Meyers 🇨🇦 @BrandonMeyersMD
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZy…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj
Janet Freeman-Daily @JFreemanDaily
Thanks @BrendonStilesMD for taking on moderating duties for #LCMS Chat this evening -- #ESMO20 summary is a great topic! #lcsm
Shawna Cullen, PhD @slcphd
#lcsm Can’t wait to talk about Keynote 5 year OS
#LCSM Chat @lcsmchat
@MimiProvenzano Hey Mimi! #lcsm
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We will get started soon. First, a few reminders… #lcsm
Brendon Stiles @BrendonStilesMD
RT @CharuAggarwalMD: @BrendonStilesMD Agree! We have seen a record number of @FDAOncology approvals, several of them have immediately chang…
Research Bot @ineelbot
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Brendon Stiles @BrendonStilesMD
T1. What is happening with KRAS? #lcsm
Devika Das, MD, MSHQS 😷 @DevikaDasMD
Hi all ! Devika Das here - VA Based thoracic oncologist from Birmingham. Listening in tonight 🙏🏽 #lcsm
#LCSM Chat @lcsmchat
@peggyddennis Hi Peggy! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat
Brendon Stiles @BrendonStilesMD
T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: If you prefer just to listen, please tweet “#LCSM” so we know you’re in the audience #lcsm
Brendon Stiles @BrendonStilesMD
@DevikaDasMD thanks for being here! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
H. Jack West, MD @JackWestMD
Med onc focused on #LungCancer in Los Angeles, based at @cityofhope & happy to join. We've had a lot of strong years for LC in past few years, & 2020 is another good one; one of the only settings for which we can say that. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. What is happening with KRAS? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
Aparna Hegde, MD @notahedge
Thoracic Onc from Birmingham #lcsm
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
Brendon Stiles @BrendonStilesMD
#LCSM
mimiprovenzano @MimiProvenzano
RT @BrendonStilesMD: By many measures, 2020 has been a pretty crappy year. But in the field of lung cancer, I would argue that 2020 has b…
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD T1. Amazing to have a treatment for ANY RAS target. Not that long ago, KRAS was considered undruggable. #lcsm
Brendon Stiles @BrendonStilesMD
T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm https://t.co/1E3khAXM0L
Hideki Matsudaira MD @matsudaira_h
RT @DevikaDasMD: Hi all ! Devika Das here - VA Based thoracic oncologist from Birmingham. Listening in tonight 🙏🏽 #lcsm
Brendon Stiles @BrendonStilesMD
@JackWestMD @cityofhope Thanks for joining. Always love your insight. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way. It is interesting to see activity in this subset of patients #LCSM
Brendon Stiles @BrendonStilesMD
T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: #LCSM
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD T1. Amazing to have a treatment for ANY RAS target. Not that long ago, KRAS was considered undruggable.…
Jae Kim @DrJaeYKim
Jae Kim, thoracic surgeon @cityofhope #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm http…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Join us in 15 minutes for tonight's #lcsm chat. To join, enter the URL “https://t.co/RK0CDZY557” in your browser and…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way.…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
Danielle Pardue @Actorielle
RT @JackWestMD: Med onc focused on #LungCancer in Los Angeles, based at @cityofhope & happy to join. We've had a lot of strong years for LC…
Brendon Stiles @BrendonStilesMD
What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: #LCSM https://t.co/eX0A7zfOgO
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: If it wasn’t for all of the great advances in lung cancer, I would mentally block out the year. #lcsm
Brendon Stiles @BrendonStilesMD
RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way.…
#LCSM Chat @lcsmchat
@DrJaeYKim @cityofhope Welcome! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: To join, enter the URL “https://t.co/RK0CDZY557” in your browser and type in #lcsm or just follow along on regular twi…
Brendon Stiles @BrendonStilesMD
@CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t.co/EzOEY8XaEI
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
H. Jack West, MD @JackWestMD
IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment. Its response rate of 32% isn't in same league as Tagrisso or Alecensa, but c'mon -- it's KRAS, & these are previously treated pts. Not a bad 1st step. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t…
Henning Willers, MD @HenningWillers
@CharuAggarwalMD @BrendonStilesMD Why you think that the ORR has come down from earlier data? #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment.…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, researcher, and advocate. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t…
Hideki Matsudaira MD @matsudaira_h
RT @AmCollSurgeons: We are very excited about The Gibbon Lecture! Important findings, critical info. #ACSCC20 #LCSM
Bob Steele @steele_bob
Will stick to the topic until after LCSM, but wanted to share that I was Dxd by a Neurologist on Monday with COVID-19 caused Dementia #lcsm
Brendon Stiles @BrendonStilesMD
@JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have failed previous treatments. #lcsm. https://t.co/EDf7XsN33X
Janet Freeman-Daily @JFreemanDaily
RT @LungCancerFaces: Deana in Los Angeles here. Tonight I’ll be tweeting from the @lcsmchat account. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: In this week’s chat we hope to review some lung cancer highlights from 2020, in particular some of the results shared…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Clinicians, researchers, patients and advocates from all over the world attended the #ESMO20 virtually. #lcsm
Andrew Hong @hongdrew
RT @JackWestMD: IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment.…
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD A1 Promising data on Sotorasib for KRAS12c- 32% ORR but 18.6 % of grade 3 or higher toxicity is a little concerning -🚨- median PFS 6.3 #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Once again, #LungCancer was heavily featured and led the way with newsworthy presentations. #lcsm https://t.co/KtMCZy…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally have a personalized therapy #KRAS #LCSM
Brendon Stiles @BrendonStilesMD
@christine_lovly Thanks for joining! Always love your input. What will be best combos? #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug combo #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Please remember to include #LCSM in ALL your tweets so the other chat participants will see them during the chat
Dr. David Tom Cooke @DavidCookeMD
Oh good grief. My thoughts are with you and your family. #LCSM
Brendon Stiles @BrendonStilesMD
RT @DevikaDasMD: @BrendonStilesMD A1 Promising data on Sotorasib for KRAS12c- 32% ORR but 18.6 % of grade 3 or higher toxicity is a little…
#LCSM Chat @lcsmchat
@steele_bob Oh, Bob. That sucks. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have…
Brendon Stiles @BrendonStilesMD
@DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lcsm https://t.co/ksWuKa5XZN
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: @JackWestMD T1. Unfortunately, it appears that duration of response is not long – at least in these patients who have…
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD A1 Promising data on Sotorasib for KRAS12c- 32% ORR but 18.6 % of grade 3 or higher toxicity is a little…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally ha…
Brendon Stiles @BrendonStilesMD
@HenningWillers There has to be a way for radiation to help! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Here are the top 5 #lcsm presentations from @APassaroMD https://t.co/yZGKiSN9dj
H. Jack West, MD @JackWestMD
Importantly, Iressa for EGFR and Xalkori for ALK were valuable steps that have been replaced by better agents over subsequent years. I suspect in a few years we'll have one or several KRAS inhibitors that eclipse sotorasib as well. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: I will announce FIVE topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
Bob Steele @steele_bob
RT @HenningWillers: @BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug comb…
#LCSM Chat @lcsmchat
@christine_lovly @BrendonStilesMD Welcome! Remember to add the #lcsm hashtag so we can all see your tweets.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. What is happening with KRAS? #lcsm
Brendon Stiles @BrendonStilesMD
Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD Your #radonc friends think combo is the way forward, and I mean drug combo and not radiation/drug comb…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. Here were the responses in NSCLC patients. Important to note that many had failed previous therapies. #lcsm http…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
Danielle Pardue @Actorielle
RT @JackWestMD: Importantly, Iressa for EGFR and Xalkori for ALK were valuable steps that have been replaced by better agents over subseque…
Brendon Stiles @BrendonStilesMD
T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lc
Henning Willers, MD @HenningWillers
A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @DevikaDasMD T1. Important to note that KRAS-mutated tumors also generally have a good response to immunotherapy. #lc
Brendon Stiles @BrendonStilesMD
RT @JackWestMD: Importantly, Iressa for EGFR and Xalkori for ALK were valuable steps that have been replaced by better agents over subseque…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: Importantly, Iressa for EGFR and Xalkori for ALK were valuable steps that have been replaced by better agents over subseque…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @CharuAggarwalMD T1. Other good drugs are also being developed in the space for other KRAS mutations. #lcsm https://t…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD It will be interesting to see how the combination data pans out. We need to also evaluate the role of other biomarkers such as STK11, PTEN and others #LCSM
#LCSM Chat @lcsmchat
RT @HenningWillers: A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm
Brendon Stiles @BrendonStilesMD
Moving to T2 soon. #lcsm
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD Yes- 74 % of patients on this study had 2 or more prior lines of therapy. ( sotorasib) #lcsm
Brendon Stiles @BrendonStilesMD
@harpreet_md Better stated! Sorry! #lcsm
Bob Steele @steele_bob
RT @HenningWillers: A1. How about for KRaS/LKB1 double mutants? They still have lower response rate?! #lcsm https://t.co/Xrac48hPJ6
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Still...given everything KRAS has been through, amazing to see progress. #lcsm https://t.co/eEweEH0kHB
Brendon Stiles @BrendonStilesMD
T2. Are there any new targets or new drugs that are compelling? #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD It will be interesting to see how the combination data pans out. We need to also evaluate the role of…
Krishan Jethwa @KrishanJethwa
Hi all! Krishan Jethwa, Rad onc at Yale, joining for my first tweet chat. Excited to listen and gather new perspectives #lcsm
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD Yes- 74 % of patients on this study had 2 or more prior lines of therapy. ( sotorasib) #lcsm
Laura Greco @lgreco_ny
Laura here from upstate NY joining late. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm
Brendon Stiles @BrendonStilesMD
@KrishanJethwa Awesome to have you here. #lcsm
#LCSM Chat @lcsmchat
@harpreet_md @BrendonStilesMD Agree! Remember to add the #lcsm hashtag to your tweets so all can see. Thanks!
Janet Freeman-Daily @JFreemanDaily
#LCSM -- yes, need tailored approach for KRAS NSCLC subtypes.
Brendon Stiles @BrendonStilesMD
@lgreco_ny Hi! Hope you are well. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Are there any new targets or new drugs that are compelling? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T1. KRAS is no longer the stepchild mutation! @KRASKickers #lcsm
#LCSM Chat @lcsmchat
@KrishanJethwa Welcome! #lcsm
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@JackWestMD That’s it! Just a good first step. Likely not the best drug in this space but glad to have options and a direction here. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm
#LCSM Chat @lcsmchat
@lgreco_ny Hey lady! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm
Brendon Stiles @BrendonStilesMD
T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical activity, including for T790M and C797S. #lcsm https://t.co/LU117VLqaK
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Are there any new targets or new drugs that are compelling? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: #LCSM -- yes, need tailored approach for KRAS NSCLC subtypes.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Lots of new data about drugs being used in different settings. And some new ones. #lcsm
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @JackWestMD That’s it! Just a good first step. Likely not the best drug in this space but glad to have options and a direc…
Christine Garcia, MD, MPH @christinemphmd
@BrendonStilesMD @kRasKickers No longer "the white whale" of mutations #lcsm
Laura Greco @lgreco_ny
@steele_bob So sorry to read this. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical ac…
Brendon Stiles @BrendonStilesMD
T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a difference for patients. #lcsm https://t.co/VtMdksacns
Hiroaki Kanemura @hirokane05
RT @TargetedOnc: Atezolizumab demonstrated a significantly longer overall survival in patients with non-small cell lung cancer who had high…
Andrew Hong @hongdrew
RT @BrendonStilesMD: T1. Early results for Sotorasib continue to look encouraging. https://t.co/aKx4gqdtya #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @JackWestMD: IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment.…
Brendon Stiles @BrendonStilesMD
RT @christinemphmd: @BrendonStilesMD @kRasKickers No longer "the white whale" of mutations #lcsm
Harpreet Singh, MD @harpreet_md
@BrendonStilesMD HER2 is interesting. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @harpreet_md: @BrendonStilesMD HER2 is interesting. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical ac…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a di…
#LCSM Chat @lcsmchat
RT @harpreet_md: @BrendonStilesMD HER2 is interesting. #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a di…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. Moving on to FOURTH generation drugs targeting EGFR. A new drug, BLU-945, showed very encouraging preclinical ac…
Brendon Stiles @BrendonStilesMD
T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk
Brendon Stiles @BrendonStilesMD
T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab and lazertinib showed high response rates in this group. Amivantamab targets both EGFR and MET. #lcsm https://t.co/nqERaBMhzn
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Poster regarding BLU-945 from $BPMC. More evidence that smart drug development is going to continue to make a di…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab…
Brendon Stiles @BrendonStilesMD
Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o
Hiroaki Kanemura @hirokane05
RT @Latinamd: Important work looking at mechanisms of resistance for newly approved #ret inhibitors for #lungcancer. Via @Annals_Oncology @…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. How will we fit BLU-945 into clinical practice? From @LeciaSequist and @StephenVLiu #lcsm https://t.co/Xj6AilVzWk
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o
Christine Lovly @christine_lovly
@BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #LCSM
Peggy Dennis @peggyddennis
@harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @DevikaDasMD: @JackWestMD That’s it! Just a good first step. Likely not the best drug in this space but glad to have options and a direc…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Definitely new options. Lots of exciting data in the EGFR space with newer drugs and combinations. #lcsm
#LCSM Chat @lcsmchat
RT @christine_lovly: @BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #…
Brendon Stiles @BrendonStilesMD
T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncologists use it as first line therapy? #lcsm https://t.co/n2GkBOBGeD
#LCSM Chat @lcsmchat
RT @peggyddennis: @harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o
Stephen V Liu @StephenVLiu
@BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple mutants now that we’re starting with the first line osimertinib but there is another allosteric in development for C797S without T790M which may have more utility. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @christine_lovly: @BrendonStilesMD I am excited about DDR inhibitors and continued evolution of epigenetic modifiers. Also - ADCs!!!! #…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncolog…
#LCSM Chat @lcsmchat
RT @StephenVLiu: @BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple muta…
Janet Freeman-Daily @JFreemanDaily
RT @peggyddennis: @harpreet_md @lcsmchat @BrendonStilesMD Exciting for sure. Just had second cycle of DS8201a. #lcsm
Brendon Stiles @BrendonStilesMD
T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: Here is Chrysalis: #lcsm https://t.co/JAWEoJh57o
Brendon Stiles @BrendonStilesMD
T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncolog…
Brendon Stiles @BrendonStilesMD
T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line immunotherapy. #lcsm https://t.co/FvLA0oPHD1
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. This is more evidence of a relentless drive and ability to make better, next generation drugs. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line im…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncolog…
kevin horgan @kevinhorgan
RT @BrendonStilesMD: T2. Potential big advance for osimertinib (Tagrisso) resistant patients. CHRYSALIS study showed combo of amivantamab…
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @BrendonStilesMD @LeciaSequist T2: it’s pretty early in the game. We realize that there will be fewer of these triple muta…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line im…
Brendon Stiles @BrendonStilesMD
T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6VtCXlFgwh
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Certainly, we would hope that these drugs come with LESS side effects. Obviously QOL is key. #lcsm
Nina Davis @ Australian Teacher & Manufacturer @ninadavis
Advocate here for LC, not medical but so refreshing to hear that one of the least funded, biggest killers on the planet is moving forward with treatments. Thank you all for what you do. #lcsm
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T2. And although not a new drug, lorlatinib looked good in the first line setting for ALK+ lung cancer. Will oncolog…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. Another #ESMO20 study – EMPOWER trial – suggested that cemiplimab (Libtayo) may be a new option for first line im…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD This is another agent, with not surprising activity. I am not sure it fits into our current paradigm #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6Vt…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6Vt…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6Vt…
#LCSM Chat @lcsmchat
RT @ninadavis: Advocate here for LC, not medical but so refreshing to hear that one of the least funded, biggest killers on the planet is m…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD This is another agent, with not surprising activity. I am not sure it fits into our current paradigm…
Erika Hlavacek @ErikaHlavacek
@BrendonStilesMD Great question. We need studies with alectinib vs. Lorlatinib now. #lcsm
Bob Steele @steele_bob
RT @JackWestMD: IMO, data on sotorasib (aka AMG 510) were a "glass half empty vs. half full" story. Many colleagues express disappointment.…
Brendon Stiles @BrendonStilesMD
T2. Would you use lorlatinib first line? #lcsm
Brendon Stiles @BrendonStilesMD
T3 coming soon.... #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6Vt…
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD A2 Studies against crizotinib. Good systemic and CNS response but given Alectinib is such a good front line drug, not practice changing for me yet. Also the toxicity is more and unique #lcsm ( probably will use it in the post alcetinib setting for now )
#LCSM Chat @lcsmchat
RT @ErikaHlavacek: @BrendonStilesMD Great question. We need studies with alectinib vs. Lorlatinib now. #lcsm
Brendon Stiles @BrendonStilesMD
RT @DevikaDasMD: @BrendonStilesMD A2 Studies against crizotinib. Good systemic and CNS response but given Alectinib is such a good front l…
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD A2 Studies against crizotinib. Good systemic and CNS response but given Alectinib is such a good front l…
CU Cancer Center @CUCancerCenter
RT @OncLive: Registration is now open! 10/8 6pm MT IPC Lung Cancer chaired by D. Ross Camidge, MD, PhD @CUCancerCenter. Register for a Q&A…
H. Jack West, MD @JackWestMD
@StephenVLiu @BrendonStilesMD @LeciaSequist I think the limitations will be how many patients there are in the wake of osimertinib acquired resistance & how common it will be for people in the broader community to get tested for a rather uncommon finding. #LCSM
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing options? #lcsm
Brendon Stiles @BrendonStilesMD
T3. Are these drugs leading to longer survival? To cures? #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: @StephenVLiu @BrendonStilesMD @LeciaSequist I think the limitations will be how many patients there are in the wake of osim…
Brendon Stiles @BrendonStilesMD
RT @JackWestMD: @StephenVLiu @BrendonStilesMD @LeciaSequist I think the limitations will be how many patients there are in the wake of osim…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Are these drugs leading to longer survival? To cures? #lcsm
Sakti Chakrabarti, MD @doctorC369
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing…
Janet Freeman-Daily @JFreemanDaily
RT @DevikaDasMD: @BrendonStilesMD A2 Studies against crizotinib. Good systemic and CNS response but given Alectinib is such a good front l…
Brendon Stiles @BrendonStilesMD
T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patients. #lcsm https://t.co/ytB1usmO5i
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/ lorlatinib may limit its adoption in 1L setting #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Are these drugs leading to longer survival? To cures? #lcsm
Manisha @Doc_Manisha_
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing…
Brendon Stiles @BrendonStilesMD
T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK excluded). #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patient…
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/…
Henning Willers, MD @HenningWillers
@BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaSequist #LCSM
Brendon Stiles @BrendonStilesMD
T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.co/uCHgIaq8mz
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patient…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK exc…
Brendon Stiles @BrendonStilesMD
Anyone know? #lcsm
Bob Steele @steele_bob
RT @JFreemanDaily: @BrendonStilesMD T2 If we use TKI that targets resistance first, without OS data, are we limiting treatment sequencing…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaS
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD The biomarker patient groups have some patients who've been on TKIs for years, but when thinking of TKI "cures" the Gleevec experience gives me pause... #LCSM
H. Jack West, MD @JackWestMD
Agree that beating crizotinib in 2020 is damning with faint praise. That's not a remotely current comparator. We also need to weigh loss of availability of lorlatinib for treatment upon progression, & a potentially challenging toxicity profile w/lorlatinib vs. alectinib. #LCSM
Stephen V Liu @StephenVLiu
@CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, and the data do look very good, I’m not sure I see a compelling reason to change my practice. I’m certainly willing to accept this as a control arm and I look forward to new combinations. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Anyone know? #lcsm
Brendon Stiles @BrendonStilesMD
T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #2020 for that matter. We are moving th needle, and improving survival! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: @BrendonStilesMD While data from CROWN study is encouraging, it is being compared to crizotinib. Toxicity concerns w/…
Christine Garcia, MD, MPH @christinemphmd
@BrendonStilesMD #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @JackWestMD: Agree that beating crizotinib in 2020 is damning with faint praise. That's not a remotely current comparator. We also nee…
Janet Freeman-Daily @JFreemanDaily
RT @StephenVLiu: @CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, a…
Brendon Stiles @BrendonStilesMD
#lcsm https://t.co/pW4gxCeOdZ
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm
Stephen V Liu @StephenVLiu
@JackWestMD @BrendonStilesMD @LeciaSequist T2: it is definitely a smaller slice of the pie than we had originally anticipated. But I can tell you when I do find it, I sure wish there were better options out there... #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD The biomarker patient groups have some patients who've been on TKIs for years, but when thinking of TKI…
Janet Freeman-Daily @JFreemanDaily
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
#LCSM Chat @lcsmchat
RT @JackWestMD: Agree that beating crizotinib in 2020 is damning with faint praise. That's not a remotely current comparator. We also nee…
Brendon Stiles @BrendonStilesMD
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
#LCSM Chat @lcsmchat
RT @StephenVLiu: @CharuAggarwalMD @BrendonStilesMD T2: I agree. This would’ve been huge 4 years ago. Now, while there’s clearly activity, a…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even years out. #lcsm
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. This was a first line randomized trial of pembrolizumab versus chemotherapy who were PD-L1 positive (EGFR/ALK exc…
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. Are the patients alive at 5 years cured? Hard to know but promising. #lcsm
Brendon Stiles @BrendonStilesMD
T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm
Henning Willers, MD @HenningWillers
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
#LCSM Chat @lcsmchat
#lcsm
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD T3 I want to see the 5 year OS data with the triplet therapy ( chemo /IO) but yes definitely impressive data #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: #lcsm https://t.co/pW4gxCeOdZ
Christine Garcia, MD, MPH @christinemphmd
Definitely one of the highlights for me from #ESMO20 #LCSM @BrendonStilesMD
#LCSM Chat @lcsmchat
RT @StephenVLiu: @JackWestMD @BrendonStilesMD @LeciaSequist T2: it is definitely a smaller slice of the pie than we had originally anticipa…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even…
Brendon Stiles @BrendonStilesMD
T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” https://t.co/PlcmpUgOPL
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD T3 I want to see the 5 year OS data with the triplet therapy ( chemo /IO) but yes definitely impressive d…
#LCSM Chat @lcsmchat
RT @christinemphmd: Definitely one of the highlights for me from #ESMO20 #LCSM @BrendonStilesMD
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” htt…
𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐇. 𝐏𝐚𝐫𝐤, 𝐌𝐃 𝐅𝐀𝐂𝐏 @ChandlerHParkMD
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Janet Freeman-Daily @JFreemanDaily
@HenningWillers @BrendonStilesMD @LeciaSequist Don't know for EGFR, but we have ROS1 patients at almost 8 years NED on crizotinib #LCSM
Stephen V Liu @StephenVLiu
@JackWestMD T2: I spend a lot of time arguing against sequencing strategies. But I agree with Jack: in this instance, it’s hard to ignore. Maybe it’s different because our initial PFS approaches three years with very well tolerated agents. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD A3. What is the longest survival without recurrence on record for a #EGFR inhibitor? 10 years? @LeciaS
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @HenningWillers @BrendonStilesMD @LeciaSequist Don't know for EGFR, but we have ROS1 patients at almost 8 years NED on c…
Brendon Stiles @BrendonStilesMD
T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median OS was 6.8 years at University of Colorado! #lcsm From @LungCancerDr https://t.co/wq7jkLfQKS
#LCSM Chat @lcsmchat
RT @StephenVLiu: @JackWestMD T2: I spend a lot of time arguing against sequencing strategies. But I agree with Jack: in this instance, it’s…
Robert Wiley @robert_wiley
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: #lcsm https://t.co/2mAxC9z3YG https://t.co/pW4gxCeOdZ
Brendon Stiles @BrendonStilesMD
T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding incidence decreases, largely due to targeted therapy. #lcsm https://t.co/AUfocXGLyA
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
Henning Willers, MD @HenningWillers
RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median…
Janet Freeman-Daily @JFreemanDaily
RT @DevikaDasMD: @BrendonStilesMD T3 I want to see the 5 year OS data with the triplet therapy ( chemo /IO) but yes definitely impressive d…
Andres F. Cardona @AndresFCardonaZ
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” htt…
Shawna Cullen, PhD @slcphd
@BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm
Brendon Stiles @BrendonStilesMD
RT @HenningWillers: @BrendonStilesMD A3. Need to keep up close surveillance. Oligorecurrence after #immunotherapy can happen any time. Even…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
Hideki Matsudaira MD @matsudaira_h
RT @JackWestMD: Importantly, Iressa for EGFR and Xalkori for ALK were valuable steps that have been replaced by better agents over subseque…
#LCSM Chat @lcsmchat
RT @slcphd: @BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @slcphd: @BrendonStilesMD Does this mean the “target” for survival “cure” may be getting longer then? Say 10 years?? #lcsm
Charu Aggarwal, MD, MPH @CharuAggarwalMD
Yes, this was HUGE. BUT, the data hasn't taken the effects of immunotherapy into account, yet. We expect the survival gains to continue to increase over the next several years! #LCSM
Danielle Pardue @Actorielle
@HenningWillers @BrendonStilesMD I hold my breath every time I see this discussed bc my mom just passed 5.5 years since dx and her only tx so far was 2 years on Avelumab. #lcsm
H. Jack West, MD @JackWestMD
@StephenVLiu @CharuAggarwalMD @BrendonStilesMD Agree. Good result, but overall vy similar to what we've already seen w/pembro & later atezolizumab in similar trial pop'ns. Need to ask a different Q or administer differently to make it novel. e.g., could you do just as well giving maint every 3 months? #LCSM
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: Yes, this was HUGE. BUT, the data hasn't taken the effects of immunotherapy into account, yet. We expect the survival…
Danielle Pardue @Actorielle
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
#LCSM Chat @lcsmchat
RT @Actorielle: @HenningWillers @BrendonStilesMD I hold my breath every time I see this discussed bc my mom just passed 5.5 years since dx…
Lecia Sequist, MD, MPH @LeciaSequist
@HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResisters #LCSM
#LCSM Chat @lcsmchat
RT @JackWestMD: @StephenVLiu @CharuAggarwalMD @BrendonStilesMD Agree. Good result, but overall vy similar to what we've already seen w/pemb…
Hideki Matsudaira MD @matsudaira_h
RT @BrendonStilesMD: What do our medical oncology friends think? Stand alone or combination therapy is best way forward? #lcsm
Brendon Stiles @BrendonStilesMD
@CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to get better. #lcsm
Henning Willers, MD @HenningWillers
RT @LeciaSequist: @HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResister
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. As @tmprowell said: “#lcsm has been transformed by #science. Deep bow to all those who had a hand in this.” htt…
H. Jack West, MD @JackWestMD
@StephenVLiu Would love to see trial data to address these Qs. Our arguments are just thought experiments. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. T3. One of my favorite papers from last year describing incredible gains in survival for ALK+ patients. Median…
Brendon Stiles @BrendonStilesMD
@LeciaSequist @HenningWillers @EGFRResisters Amazing! #lcsm
Hideki Matsudaira MD @matsudaira_h
RT @CharuAggarwalMD: @BrendonStilesMD What is NOT happening with KRAS. We have not one, but 2 active drugs, with sotorasib leading the way.…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
Brendon Stiles @BrendonStilesMD
RT @JackWestMD: @StephenVLiu @CharuAggarwalMD @BrendonStilesMD Agree. Good result, but overall vy similar to what we've already seen w/pemb…
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD T3 Also looking to look at some real world follow up data with patients with co-morbidities and see if this OS data translates ? #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @JackWestMD: @StephenVLiu Would love to see trial data to address these Qs. Our arguments are just thought experiments. #LCSM
Henning Willers, MD @HenningWillers
@LeciaSequist @BrendonStilesMD @EGFRResisters A3. That has to be a true cure! Is the patient still on the drug? Would you ever stop? #LCSM
Brendon Stiles @BrendonStilesMD
T4 coming....earlier stage lung cancer. Finally something I know about. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
#LCSM Chat @lcsmchat
RT @LeciaSequist: @HenningWillers @BrendonStilesMD I have a patient who started gefitinib in 2002 and has not relapsed yet. 💕 @EGFRResister
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @CharuAggarwalMD Yes..amazing to consider this was pre-immunotherapy and pre-next gen targeted therapy. Only going to…
Patty Watkins @Pattybeatslungc
RT @IASLC: This #LiquidBiopsy20 presentation by Dr. Natasha Leighl will give an in-depth look at integrating liquid biopsy into clinical p…
#LCSM Chat @lcsmchat
RT @JackWestMD: @StephenVLiu Would love to see trial data to address these Qs. Our arguments are just thought experiments. #LCSM
Brendon Stiles @BrendonStilesMD
T4. What is happening in earlier stage lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @LeciaSequist @BrendonStilesMD @EGFRResisters A3. That has to be a true cure! Is the patient still on the drug? Would y…
Janet Freeman-Daily @JFreemanDaily
@HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the drug forever to keep the cancer controlled? Or is it "chronic illness"? #LCSM
Matthew Steliga MD @SteligaMD
@BrendonStilesMD @NEJM Thank me for sharing- I will have to read for details. I wonder if early detection played some role in decreasing mortality as well. #LCSM.
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the dr…
Christine Lovly @christine_lovly
@BrendonStilesMD @NEJM True - for NSCLC. But not for SCLC. We need a lot more studies to understand lineage plasticity, tumor heterogeneity, + new treatment paradigms for SCLC. Overall survival of 12mo with “modern” chemotherapy plus immunotherapy is clearly not enough. #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T3. At #ESMO20, KEYNOTE-024 showed the potential of long term survival after immunotherapy for PD-L1 positive patient…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the dr…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
#LCSM Chat @lcsmchat
RT @christine_lovly: @BrendonStilesMD @NEJM True - for NSCLC. But not for SCLC. We need a lot more studies to understand lineage plasticity…
Brendon Stiles @BrendonStilesMD
T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decrease in recurrences in the brain. #lcsm https://t.co/IKBCTUJPMZ
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decreas…
Brendon Stiles @BrendonStilesMD
T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T3. Incredible potential exists with combination regimens to extend survival in those patients with PD-L1 <50%. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg
Brendon Stiles @BrendonStilesMD
T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T3. Great article in @NEJM last month regarding advances in lung cancer treatment. Mortality decreases exceeding inc…
Shawna Cullen, PhD @slcphd
@BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than SOC? #lcsm
Stephen V Liu @StephenVLiu
@JackWestMD T2: KRAS is more common. Huge impact. Very impressive safety profile (critical). My enthusiasm for the ultra high “disease control rate” was tempered when they reported a fairly short median duration of stable disease. But undeniably, an important step. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decreas…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Results were published in the @nejm #lcsm https://t.co/iv9yxhIQRg
H. Jack West, MD @JackWestMD
T4) ADAURA CNS relapse rate was big story, but I really wish results had included analysis by baseline brain MRI or not, since global trial had variable staging practices. Is osi benefit from treating small brain mets missed w/o MRI? #LCSM
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T4. More data presented regarding adjuvant osimertinib after surgery for EGFR+ patients (ADAURA). Remarkable decreas…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr
Brendon Stiles @BrendonStilesMD
T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https://t.co/fwi6S56LW2
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T4. What is happening in earlier stage lung cancer? #lcsm
Christine Garcia, MD, MPH @christinemphmd
Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat
Brendon Stiles @BrendonStilesMD
Great point. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @JackWestMD: T4) ADAURA CNS relapse rate was big story, but I really wish results had included analysis by baseline brain MRI or not, si…
Brendon Stiles @BrendonStilesMD
T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv
Maaz Afghan @maazafghan
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Charu Aggarwal, MD, MPH @CharuAggarwalMD
@StephenVLiu @JackWestMD That is the point right, this is a small step. We cannot let it be tempered by the "low" RR. We all know that this is not going to be an easy win. Step in the right direction. Small step #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @slcphd: @BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https…
Clee Van Leef @LeefVan
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
Andrea Borondy Kitts @findlungcancer
So well deserved - Congratulations! @CriswellAngela Angela Criswell Wins the the 2020 Timothy W. Mullett, MD, Lung Cancer Prevention Award https://t.co/zuWuCpEOzr #lcsm @DrewMoghanaki @BrendonStilesMD @sands_jacob @SandlerRhodes
Janet Freeman-Daily @JFreemanDaily
RT @christinemphmd: Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat https://t.co/sYe…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv
Brendon Stiles @BrendonStilesMD
T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier stage patients is the path forward. #lcsm
Henning Willers, MD @HenningWillers
@BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. You can see the results presented here by Dr. Tsuboi. #lcsm https://t.co/V7c2GpkHCr
#LCSM Chat @lcsmchat
RT @slcphd: @BrendonStilesMD Very interested in sequencing here (early stage). What regimens in what order are showing greater effect than…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Adjuvant Osimertinb markedly decreased recurrences. Is this important to cancer patients or just OS? #lcsm https…
#LCSM Chat @lcsmchat
RT @christinemphmd: Encouraging to see therapy options for patients with #lungcancer improving each year! #lcsm @lcsmchat
Matthew Steliga MD @SteligaMD
@BrendonStilesMD @NEJM Thank you for sharing- I will have to read for details. I wonder if early detection played some role in decreasing mortality as well. #LCSM.
#LCSM Chat @lcsmchat
RT @JackWestMD: T4) ADAURA CNS relapse rate was big story, but I really wish results had included analysis by baseline brain MRI or not, si…
Brendon Stiles @BrendonStilesMD
T4. Another important study was the LungART trial which evaluated post operative radiation (PORT) in patients with resected N2 disease. Good summary by @jsoriamd #lcsm https://t.co/xf99hkzepu
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm
Santhosh Ambika @RenoHemonc
@StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD A4 ADAURA- will be the best case for shared decision making in the adjuvant setting. PORT - puts to rest what we kind of knew so yes practice changing. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv
#LCSM Chat @lcsmchat
RT @CharuAggarwalMD: @StephenVLiu @JackWestMD That is the point right, this is a small step. We cannot let it be tempered by the "low" RR.…
Brendon Stiles @BrendonStilesMD
T4. LungART failed to show improvement in DFS with addition of adjuvant radiation, although it did decrease mediastinal relapse. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD T4. For localized disease only cure is important, min 5 year survival without recurrence #lcsm
H. Jack West, MD @JackWestMD
T4) LUNGART trial directly tested role of post-op radiation for stage IIIA N2 resected NSCLC & showed no benefit w/RT. This is probably practice-changing in a setting in which we have largely practiced w/remarkably little direct data. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Another important study was the LungART trial which evaluated post operative radiation (PORT) in patients with re…
#LCSM Chat @lcsmchat
RT @RenoHemonc: @StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD A4 ADAURA- will be the best case for shared decision making in the adjuvant setting. PORT - puts to rest…
Brendon Stiles @BrendonStilesMD
T4. LungART study showed a tradeoff – decreased progression/recurrence with radiation came at expense of toxicity and a slight increase in 2nd cancers. #lcsm https://t.co/LpEgZGMyt0
#LCSM Chat @lcsmchat
RT @JackWestMD: T4) LUNGART trial directly tested role of post-op radiation for stage IIIA N2 resected NSCLC & showed no benefit w/RT. This…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. LungART study showed a tradeoff – decreased progression/recurrence with radiation came at expense of toxicity and…
Brendon Stiles @BrendonStilesMD
RT @JackWestMD: T4) LUNGART trial directly tested role of post-op radiation for stage IIIA N2 resected NSCLC & showed no benefit w/RT. This…
Janet Freeman-Daily @JFreemanDaily
RT @RenoHemonc: @StephenVLiu @JackWestMD controlling MAP3k/PI3K SHP-2 pathway very important for durable response with Soto.#LCSM
Brendon Stiles @BrendonStilesMD
T4. Although we can’t recommend adjuvant PORT as standard of care, both arms showed great DFS for stage III disease. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. LungART failed to show improvement in DFS with addition of adjuvant radiation, although it did decrease mediastin…
Jen Buhay, PhD 🧬 @JenBuhayPhD
RT @CharuAggarwalMD: That is exactly my take, we cannot expect to see the same RRs, and the responses may not be durable, but we finally ha…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Although we can’t recommend adjuvant PORT as standard of care, both arms showed great DFS for stage III disease.…
Henning Willers, MD @HenningWillers
@JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have negated any survival benefit from reducing local recurrence. Just like PORT meta-analysis [sigh] #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have…
Brendon Stiles @BrendonStilesMD
T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a single dose of atezolizumab. #lcsm https://t.co/DCepMx3Ofe
Brendon Stiles @BrendonStilesMD
T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvant immunotherapy. @bmassutis #lcsm https://t.co/S7kEfuUVAb
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a si…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvan…
Henning Willers, MD @HenningWillers
@BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation increases risk of lung cancer to my knowledge. Generally radiation induced cancer also have latency > 5 years. #lcsm
Brendon Stiles @BrendonStilesMD
T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm
Brendon Stiles @BrendonStilesMD
@HenningWillers Agree. #lcsm
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm
Elliot Servais, MD, FACS @ElliotServaisMD
@HenningWillers @JackWestMD #LCSM Agreed, need to see manuscript, but this will be practice changing I suspect.
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @JackWestMD A4. We will have to review paper. Difficult trial with large fields and unexpected toxicity that could have…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Also more great w.ork on neoadjuvant immunotherapy for lung cancer. PRINCEPS trial showed 14% MPR with just a si…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Such study designs allow for great translational research that will help us better select patients for neoadjuvan…
Janet Freeman-Daily @JFreemanDaily
RT @HenningWillers: @BrendonStilesMD A4. The increase in 2nd cancers difficult to understand. No other data to suggest that lung radiation…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T4. Results were also presented from the IoNESCO trial with neoadjuvant durvalumab with robust 18.6% MPR. #lcsm
H. Jack West, MD @JackWestMD
@HenningWillers Unfortunately, while there may be nuances, I think it will sway practice in a setting where we don't have high quality data to refute it. I feel like our practice has been guided more by rationale & intuition, so even flawed trial will have outsized influence. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @ElliotServaisMD: @HenningWillers @JackWestMD #LCSM Agreed, need to see manuscript, but this will be practice changing I suspect.
Henning Willers, MD @HenningWillers
@BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, ECE), upper lobe location who might still benefit from #radiotherapy. Modern IMRT/VMAT can be used with little toxicity #lcsm
#LCSM Chat @lcsmchat
RT @JackWestMD: @HenningWillers Unfortunately, while there may be nuances, I think it will sway practice in a setting where we don't have h…
Brendon Stiles @BrendonStilesMD
@HenningWillers New phenomenon. Anti-abscopal effect? #lcsm
Brendon Stiles @BrendonStilesMD
RT @HenningWillers: @BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, E…
#LCSM Chat @lcsmchat
RT @HenningWillers: @BrendonStilesMD A4. Will need subset analysis to possibly identify patients with unfavorable tumors (multiple nodes, E…
Brendon Stiles @BrendonStilesMD
T5 on way.... #lcsm
Henning Willers, MD @HenningWillers
@JackWestMD sadly you may be right (ok I am somewhat biased) #lcsm
Brendon Stiles @BrendonStilesMD
T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #lcsm
Laronica Conway @louisianagirl91
RT @JFreemanDaily: @HenningWillers @LeciaSequist @BrendonStilesMD @EGFRResisters Can you call it a "cure" if you have to keep taking the dr…
Brendon Stiles @BrendonStilesMD
T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: @HenningWillers New phenomenon. Anti-abscopal effect? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #l
Laronica Conway @louisianagirl91
RT @CharuAggarwalMD: These are the most impressive curves in #NSCLC and probably the most exciting and uplifting data from @myESMO and #202
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #l
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. I think they are steadily getting better. Many are free to patients and advocates, but could better engage. #LCSM
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #l
Laronica Conway @louisianagirl91
RT @BrendonStilesMD: T2. A phase I study for EGFR exon 20 patients. By @ZpiotrowskaMD and shared by @DrSanjayPopat #lcsm https://t.co/6Vt…
Brendon Stiles @BrendonStilesMD
T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4
Matthew Steliga MD @SteligaMD
@BrendonStilesMD T4. It would also be really interesting to use biomarker driven therapy in the immediate preop / perioperative time period. We know circulating tumor cells can ⬆️ with surgery. #LCSM.
Matthew Steliga MD @SteligaMD
RT @BrendonStilesMD: T4. In my opinion, continuing to move biomarker driven therapy into neoadjuvant and/or adjuvant treatment for earlier…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. How are virtual conferences working out and how can patients/advocates participate? What does everyone think? #l
Laronica Conway @louisianagirl91
RT @BrendonStilesMD: T1. This is important, as KRAS was long thought to be “undruggable” #lcsm https://t.co/yT8IGcfyop
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD The virtual conferences do give advocates more access to presentations, yet less interaction with experts. #lcsm
Brendon Stiles @BrendonStilesMD
T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: The virtual conferences do give advocates more access to presentations, yet less interaction with experts. #lcsm
virginia litle @vlitlemd
RT @BrendonStilesMD: T3. Truly remarkable 5-year overall survival of 31.9% in PD-L1 >50% group (vs. 16% in chemo group). #lcsm https://t.c…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. I thought #ESMO20 did a great job. So did @tmprowell #lcsm https://t.co/Rl7f0Iiie4
#LCSM Chat @lcsmchat
RT @SteligaMD: @BrendonStilesMD T4. It would also be really interesting to use biomarker driven therapy in the immediate preop / perioperat…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD The virtual conferences do give advocates more access to presentations, yet less interaction with exper…
Brendon Stiles @BrendonStilesMD
T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Certainly not having to travel is nice and may ultimately allow for more collaborative efforts. #lcsm
Brendon Stiles @BrendonStilesMD
T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo
Laronica Conway @louisianagirl91
@BrendonStilesMD Gaaaaahh can’t believe I forgot about the chat!!! This is good stuff!! I’ll have to catch up on all this good info later!! #lcsm
Brendon Stiles @BrendonStilesMD
T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost. #lcsm
Devika Das, MD, MSHQS 😷 @DevikaDasMD
@BrendonStilesMD Great option for those that can’t travel. Needs to be free for all patients and advocates! But is potentially limiting for junior faculty like me who count on in person networking for mentorship... so 50-50 - hybrid model is key! #lcsm
Brendon Stiles @BrendonStilesMD
@louisianagirl91 Always forgiven! #lcsm
virginia litle @vlitlemd
Progress sorely needed #Lcsm For our patients. Good news indeed
Brendon Stiles @BrendonStilesMD
RT @DevikaDasMD: @BrendonStilesMD Great option for those that can’t travel. Needs to be free for all patients and advocates! But is potenti…
mimiprovenzano @MimiProvenzano
@BrendonStilesMD Silver linings! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm
Pashtoon Kasi MD, MS @pashtoonkasi
RT @PestanaRC: Very nice article by @pashtoonkasi on ctDNA kinetics and response to immunotherapy!
Brendon Stiles @BrendonStilesMD
@DevikaDasMD Great, great points! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo
Elliot Servais, MD, FACS @ElliotServaisMD
@BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times with a hybrid approach. In-person conferences with option to remote in. Would maximize impact and reach of conferences.
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost.…
Janet Freeman-Daily @JFreemanDaily
@BrendonStilesMD T5. True, but virtual meetings also encourage more in-seat time, with fewer breaks. Also, most people now have to parallel process conferences with bandwidth demands from work (and sometimes family). #LCSM
#LCSM Chat @lcsmchat
@BrendonStilesMD And the photo ops! #lcsm
#LCSM Chat @lcsmchat
RT @DevikaDasMD: @BrendonStilesMD Great option for those that can’t travel. Needs to be free for all patients and advocates! But is potenti…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Ability to review sessions “on demand” allows people to not have to race from session to session. #lcsm
Brendon Stiles @BrendonStilesMD
T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. There is a sense of screen fatigue however…. #lcsm https://t.co/b8admpGlwo
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. And I certainly miss the informal conversations that happen between sessions. Networking opportunities are lost.…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8
#LCSM Chat @lcsmchat
RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times w…
Brendon Stiles @BrendonStilesMD
RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times w…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @BrendonStilesMD T5. True, but virtual meetings also encourage more in-seat time, with fewer breaks. Also, most people n…
Stephen V Liu @StephenVLiu
RT @BrendonStilesMD: T4. #lcsm Great recap by @StephenVLiu and @OncoAlert: https://t.co/rQvh77I8fv
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8
Janet Freeman-Daily @JFreemanDaily
RT @ElliotServaisMD: @BrendonStilesMD T5/ #LCSM I would love to see the experience with virtual conferences extend to post-pandemic times w…
Janet Freeman-Daily @JFreemanDaily
RT @lcsmchat: @BrendonStilesMD And the photo ops! #lcsm
Brendon Stiles @BrendonStilesMD
T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer! #lcsm https://t.co/o5h6pXcuP7 Join @iaslc on October 16-17.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Nice review of virtual conferences here. #lcsm https://t.co/SH24CQtYi8
Brendon Stiles @BrendonStilesMD
Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Elliot Servais, MD, FACS @ElliotServaisMD
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
Brendon Stiles @BrendonStilesMD
Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. https://t.co/fSX4H8ozpK
Laronica Conway @louisianagirl91
@BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work while still listening and bookmarking links to pertinent info. Free to all was very beneficial. I also liked seeing others questions in the chat box. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
Janet Freeman-Daily @JFreemanDaily
RT @DevikaDasMD: @BrendonStilesMD Great option for those that can’t travel. Needs to be free for all patients and advocates! But is potenti…
Brendon Stiles @BrendonStilesMD
Please share your closing thoughts! #lcsm
Elizabeth McKenna @ElizSMcKenna
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. http…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. http…
Upstage Lung Cancer @UpstageLungCanc
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
Brendon Stiles @BrendonStilesMD
Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer
#LCSM Chat @lcsmchat
RT @louisianagirl91: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work whi…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Please share your closing thoughts! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer
Janet Freeman-Daily @JFreemanDaily
@lcsmchat @BrendonStilesMD And the competitions for longest ribbon train ... #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
Christine Garcia, MD, MPH @christinemphmd
@BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to find ways to improve. More affordable as it's tough to travel - both time, $, finding coverage. However #LCSM has def helped!
Danielle Pardue @Actorielle
RT @louisianagirl91: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work whi…
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Almost time to wind the chat down. This has been an incredible discussion. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Great video recap of #ESMO20 #LungCancer #lcsm from @peters_solange @DrSanjayPopat @APassaroMD and Dr. Cappuzzo. http…
Christian Rolfo @ChristianRolfo
Great #LCSM discussion with @BrendonStilesMD with very important questions! Thanks Brendon! Great participation as always from @StephenVLiu @n8pennell and @CharuAggarwalMD @lcsmchat
Janet Freeman-Daily @JFreemanDaily
RT @louisianagirl91: @BrendonStilesMD T5: I “watched” the FREE virtual @AACR patient advocate webinar today. I loved being able to work whi…
Elliot Servais, MD, FACS @ElliotServaisMD
@BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD.
H. Jack West, MD @JackWestMD
Special thanks to @BrendonStilesMD for preparing for & then moderating the #LCSM chat masterfully.
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Please share your closing thoughts! #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: Thanks to all of the #lcsm community who joined. And BIG thanks to #ESMO20 for highlighting #LungCancer
Brendon Stiles @BrendonStilesMD
RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to fin…
Janet Freeman-Daily @JFreemanDaily
RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to fin…
Danielle Pardue @Actorielle
Thank you for everything, @BrendonStilesMD and @lcsmchat! #lcsm
#LCSM Chat @lcsmchat
Thanks for moderating tonight’s #LCSM chat @BrendonStilesMD. We appreciate you!
#LCSM Chat @lcsmchat
RT @christinemphmd: @BrendonStilesMD Def miss the networking opportunities, social events, and stepping out of your own clinic space to fin…
#LCSM Chat @lcsmchat
RT @ChristianRolfo: Great #LCSM discussion with @BrendonStilesMD with very important questions! Thanks Brendon! Great participation as alwa…
#LCSM Chat @lcsmchat
RT @ElliotServaisMD: @BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD.
#LCSM Chat @lcsmchat
RT @JackWestMD: Special thanks to @BrendonStilesMD for preparing for & then moderating the #LCSM chat masterfully.
Christian Rolfo @ChristianRolfo
And @ialsc liquid biopsy tomorrow@and Saturday! https://t.co/PJu8nL0RnZ https://t.co/o1a7EsUZ2H
Janet Freeman-Daily @JFreemanDaily
Thanks to moderator @BrendonStilesMD for preparing a great set of tweets for tonight's #LCSM Chat on #lungcancer at #ESMO20!
Hideki Matsudaira MD @matsudaira_h
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
Brendon Stiles @BrendonStilesMD
We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's thoughts. Thanks for taking time from your busy schedules. Miss you all!
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Thanks to moderator @BrendonStilesMD for preparing a great set of tweets for tonight's #LCSM Chat on #lungcancer at #ESM
Janet Freeman-Daily @JFreemanDaily
RT @ElliotServaisMD: @BrendonStilesMD #LCSM This is a great forum. Congrats to #LCSM and the moderator @BrendonStilesMD.
Laronica Conway @louisianagirl91
RT @Actorielle: Thank you for everything, @BrendonStilesMD and @lcsmchat! #lcsm
Deb Smith 🇺🇸🗽💙🎉🌅🍾 @debsmithbeach
@louisianagirl91 @BrendonStilesMD #LCSM Me too....sorry. I’ll look at transcript tomorrow.
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's th…
Christine Garcia, MD, MPH @christinemphmd
@BrendonStilesMD T5. Not running from the far ends of a conference center then getting caught in the crowds also helps! #LCSM
Janet Freeman-Daily @JFreemanDaily
RT @JackWestMD: Special thanks to @BrendonStilesMD for preparing for & then moderating the #LCSM chat masterfully. https://t.co/yjvyqkg0Ob
Janet Freeman-Daily @JFreemanDaily
RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's th…
Brendon Stiles @BrendonStilesMD
Still room for this - sure to be a great conference. #lcsm
Janet Freeman-Daily @JFreemanDaily
RT @christinemphmd: @BrendonStilesMD T5. Not running from the far ends of a conference center then getting caught in the crowds also helps!…
Henning Willers, MD @HenningWillers
@BrendonStilesMD Thank you for making it multidisciplinary :-) #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Still room for this - sure to be a great conference. #lcsm
Christine Garcia, MD, MPH @christinemphmd
@lcsmchat @BrendonStilesMD Thanks! Great moderating @BrendonStilesMD! #LCSM @LSCM
Stephen V Liu @StephenVLiu
RT @BrendonStilesMD: T5. Speaking of virtual conferences...Don't forget to register for the 2020 North America Conference on Lung Cancer!…
ann price @aepriceny
@BrendonStilesMD #lcsm Thanks for all you do Dr.Stiles. Cancer free, now, but all the ideas you guy knock around every month could prolong my life for another 5 if old age doesn’t get me first. Xxx.
Lung Cancer Sux @LungCancerSux
RT @JackWestMD: Special thanks to @BrendonStilesMD for preparing for & then moderating the #LCSM chat masterfully.
Sara Whitlock @sjwhitlock
@BrendonStilesMD @lcsmchat Great job as always. Thanks for all you do. #lcsm
Harpreet Singh, MD @harpreet_md
@BrendonStilesMD Wonderful chat! #LCSM
Janet Freeman-Daily @JFreemanDaily
Check out the @IASLC hot topic conference on liquid biopsy Oct 2-3! #LCSM
Laronica Conway @louisianagirl91
RT @BrendonStilesMD: We really appreciate everyone for joining the #lcsm community tonight. Always good to catch up and hear everyone's th…
Brendon Stiles @BrendonStilesMD
@aepriceny You are too young and energetic for old age to get you. Especially now with your modeling career taking off. Thanks for joining! #lcsm 🥰
Brendon Stiles @BrendonStilesMD
@sjwhitlock @lcsmchat Let's talk soon! #lcsm
Brendon Stiles @BrendonStilesMD
RT @aepriceny: #lcsm @aepriceny celebrating 9month CT scan Cancer Free! Grateful and happy to be here!
Brendon Stiles @BrendonStilesMD
Good night all! #lcsm
Bruno Larvol 🧢 @brunolarvol
RT @JackWestMD: Med onc focused on #LungCancer in Los Angeles, based at @cityofhope & happy to join. We've had a lot of strong years for LC…
May Cho @MayCho_MD
Can’t wait for the future when we can define duration of IO smarter than what we currently do!
Bob Steele @steele_bob
Good night folks. Look forward to seeing you at next month's Lung Cancer Social Media group chat. #lcsm
Bruno Larvol 🧢 @brunolarvol
RT @JackWestMD: T4) LUNGART trial directly tested role of post-op radiation for stage IIIA N2 resected NSCLC & showed no benefit w/RT. This…
Pashtoon Kasi MD, MS @pashtoonkasi
RT @MayCho_MD: Can’t wait for the future when we can define duration of IO smarter than what we currently do!
Bruno Larvol 🧢 @brunolarvol
RT @JackWestMD: @HenningWillers Unfortunately, while there may be nuances, I think it will sway practice in a setting where we don't have h…
Bob Steele @steele_bob
I have a video that will be shown at the conference - dealing with COVID-19. #LCSM
Conservatives4PublicOption @PubOptConserv
RT @OurWarOnCancer: #LungCancer is the #1cancerKiller (160,000/yr in US!) There is a painless screening test available 4 people at high ris…
Janet Freeman-Daily @JFreemanDaily
The transcript for tonight's #LCSM Chat "Crazy year, crazy progress–#lungcancer at #ESMO20" is here: https://t.co/hpvHTNXOHl
Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye
RT @pashtoonkasi: 🆕My📝 @ASCO📰 💡“Kinetics of #LiquidBiopsies in Predicting Response to #Immunotherapy.”📉🆚📈💭 @ASCO_pubs #ASCODailyNews 🙏🏽…
#LCSM content from Twitter.